Resumen de Bone loss induced by cancer treatments in breast and prostate cancer patients

Santos Castañeda Sanz, A. M. Casas Fernández de Tejerina, Aránzazu González del Alba, Guillermo Martínez Díaz Guerra, Xavier Nogués Solán, Cristina Ojeda Thies, Oscar Torregrosa Suau, Álvaro Rodríguez Lescure

• Cancer and cancer therapies are a major factor risk for osteoporosis due to bone loss and deterioration of bone microarchitecture. Both factors contribute to a decrease in bone strength and, consequently, increased bone fragility and risk of fracture. Cancer-associated bone loss is a multifactorial process, and optimal interdisciplinary management of skeletal health, accurate assessment of bone density, and early diagnosis are essential when making decisions aimed at reducing bone loss and fracture risk in patients who have received or are receiving treatment for cancer. In this document, a multidisciplinary group of experts collected the latest evidence on the pathophysiology of osteoporosis and its prevention, diagnosis, and treatment with the support of the Spanish scientific society SEOM. The aim was to provide an up-to-date and in-depth view of osteoporotic risk and its consequences, and to present a series of recommendations aimed at optimizing the management of bone health in the context of cancer.